NeuroSense Therapeutics Warrant
NRSNW
5 hedge funds and large institutions have $605K invested in NeuroSense Therapeutics Warrant in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$379K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$134K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$59.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $388K | +$379K | +425,000 | New |
|
|
2
Hudson Bay Capital Management
Stamford,
Connecticut
| $137K | +$134K | +150,000 | New |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $61K | +$59.3K | +66,606 | New |
|
|
EAM
4
Empery Asset Management
New York
| $15K | +$143K | +160,000 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $4K | +$4K | +4,491 | New |
|
NRSNW Hedge Fund Activity: Q4 2021 in Review
5 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q4 2021, worth a combined $605K.
Buyers outnumbered sellers: 5 funds opened new NRSNW positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $379K.
- 5 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $605K of NeuroSense Therapeutics Warrant stock for Q4 2021.
- 5 funds opened new NeuroSense Therapeutics Warrant positions in Q4 2021 and 0 closed out, a net change of +5 holders.
- The largest NeuroSense Therapeutics Warrant buyer in Q4 2021 was Armistice Capital, an estimated $379K added.
Based on aggregated 13F filings for Q4 2021.